Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies

Br J Pharmacol. 2017 Jul;174(13):1895-1907. doi: 10.1111/bph.13780. Epub 2017 Apr 26.


Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS, and one of the most common causes of disability in young adults. Over the last decade, new disease-modifying therapies have emerged, including monoclonal antibodies (mAbs) that provide highly targeted therapies with greater efficacy than platform therapies. In particular, monoclonal antibodies directed against CD20-positive B cells have shown remarkable results in recent clinical trials and renewed interest in the mechanism of B cell-depleting therapies to ameliorate relapse activity and progression in MS. Here, we review the mechanisms of action and clinical evidence of approved and emerging mAbs, with a focus on B cell-targeted therapies.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / pharmacology*
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / immunology
  • Humans
  • Multiple Sclerosis / drug therapy*


  • Antibodies, Monoclonal